Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Vocimagene amiretrorepvec |
| Synonyms | |
| Therapy Description |
Vocimagene amiretrorepvec (DB107-RRV) is a retroviral vector encoding yeast cytosine deaminase, which converts the prodrug flucytosine into 5-fluorouracil upon infection of tumor cells, potentially leading to tumor cell death (PMID: 22547150, PMID: 30676111). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Vocimagene amiretrorepvec | T5.0002|Toca 511|DB107-RRV | Chemotherapy - Antimetabolite 14 | Vocimagene amiretrorepvec (DB107-RRV) is a retroviral vector encoding yeast cytosine deaminase, which converts the prodrug flucytosine into 5-fluorouracil upon infection of tumor cells, potentially leading to tumor cell death (PMID: 22547150, PMID: 30676111). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01985256 | Phase I | Vocimagene amiretrorepvec | Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | Completed | USA | 0 |